FDA NDI Notification for EGCG 98% & Curcumin 95%
When concentrated botanical extracts trigger an NDI filing under 2024–2026 FDA guidance.
Do EGCG 98% or Curcumin 95% Require FDA NDI Notification?
An FDA New Dietary Ingredient Notification (NDIN) is a mandatory 75-day premarket filing required under Section 413 of the FD&C Act (21 U.S.C. § 350b) for any dietary ingredient not marketed in the U.S. before October 15, 1994 — or for a pre-DSHEA ingredient whose manufacturing has "significantly chemically altered" it beyond its traditional form. Concentrated botanical extracts such as EGCG 98% (Camellia sinensis) and Curcumin 95% (Curcuma longa), produced via chromatographic purification or solvent crystallization, are highly likely to meet FDA's chemical-alteration threshold and therefore require an NDIN with a full safety dossier before U.S. market entry.
What Is the FDA's Updated NDI Framework (2024–2026)?
On March 5, 2024, FDA issued its final guidance — "Dietary Supplements: New Dietary Ingredient Notification Procedures and Timeframes" — formalizing Section V of the 102-page 2016 draft guidance. On April 3, 2024, a companion draft guidance introduced the NDIN Master File program, allowing manufacturers to submit confidential identity, manufacturing, and safety data that authorized third parties can reference in their own NDINs without resubmitting proprietary studies. By June 2025, FDA released educational videos and a fact sheet highlighting five common NDIN pitfalls — including insufficient identity information and the false assumption that a competitor's prior NDIN covers your product.
Grandfathered vs. New: The October 15, 1994 Dividing Line
Ingredients documented as marketed in U.S. dietary supplements before October 15, 1994 are "grandfathered" and exempt from NDIN filing. Crude turmeric powder and conventional green tea leaf fall into this category. However, a grandfathered ingredient loses its exempt status if post-1994 manufacturing changes alter its chemical composition or structure — including the use of different solvents, novel purification steps, or substantially higher extraction temperatures.
The NDI Master File: Protecting Proprietary Data
An NDIN Master File contains confidential identity, manufacturing, and safety information that the file owner submits to FDA. The owner can grant a written right of reference to downstream supplement manufacturers, who then cite the Master File in their own NDINs rather than regenerating costly toxicology and process data. This mechanism — modeled on drug Master Files — directly addresses the industry's long-standing "borrowed science" problem where competitors piggybacked on public NDIN data.
Does High-Purity Extraction Trigger "Significant Chemical Alteration"?
FDA's 2016 revised draft guidance (Sections IV-A and IV-B, still in draft as of 2026) defines "chemical alteration" broadly. Industry stakeholders such as the American Botanical Council (ABC) have confirmed that column chromatography, precipitation/crystallization, and substantial solvent-polarity changes alter chemical composition enough to create a new dietary ingredient. The FDA-cited example of "98% pure apigenin obtained from parsley" via chromatographic purification applies directly to EGCG 98% and Curcumin 95%.
| Extraction Method | FDA View on Chemical Alteration | NDI Notification Required? |
|---|---|---|
| Water infusion / decoction (traditional tea) | Not chemically altered; consistent with food-supply use | No |
| Ethanol/water tincture (crude 40–60% polyphenol extract) | Minor alteration — may retain pre-DSHEA status if documented | Likely No |
| Major solvent polarity change (e.g., hexane → 70% ethanol) | "Generally results in a significant change in chemical profile" (ABC/FDA) | Yes |
| Column chromatography / preparative HPLC (≥95% isolate) | Creates a chemically distinct ingredient; explicit FDA draft-guidance example | Yes |
| Precipitation / crystallization (Curcumin ≥95%) | Selectively removes curcuminoid congeners and co-metabolites | Yes |
| Supercritical CO₂ at extreme pressure/temperature | Case-by-case; may or may not substantially alter chemical profile | Case-by-case |
What Must an NDI Safety and Manufacturing Dossier Include?
Per the March 2024 final guidance, 21 C.F.R. § 190.6, and the June 2025 FDA fact sheet, a complete NDIN must contain:
- NDI Identity: Latin binomial (including author citation), plant part, specification sheet with purity, strength, impurities, and contaminants.
- Manufacturing Process: Extraction solvents, purification steps, process controls, and cGMP compliance under 21 CFR Part 111.
- Safety Evidence: History of use (if applicable to the specific form), toxicological studies (Ames test, chromosomal aberration assay, 90-day repeated-dose oral toxicity), published clinical data, and adverse event analysis.
- Supplement Description: NDI level per serving, all other dietary and non-dietary ingredients, labeled conditions of use.
- Full-text References: Complete reprints of all cited publications — abstracts alone are rejected.
21 CFR 111 cGMP Validation for Botanical Extraction
Beyond the NDIN, ongoing compliance with 21 CFR Part 111 (Current Good Manufacturing Practice for Dietary Supplements) requires identity testing under § 111.75, full batch traceability from raw botanical to finished extract, validated HPLC-DAD or HPLC-MS analytical methods using pharmacopeial reference standards, and documented stability data.
Toxicological Studies: What FDA Expects
For high-purity isolates without extensive food-use history, FDA expects a genotoxicity battery (bacterial reverse mutation / Ames test + in vitro chromosomal aberration) and a subchronic 90-day oral toxicity study in rodents, conducted under GLP. These studies must match the exact NDI specification — data generated on a different purity grade or a crude extract may be rejected.
Blue Eye Biotech's NDI-Compliant Raw Material Dossiers
Blue Eye Biotech provides pre-assembled raw-material documentation packages for high-purity botanical extracts — including green tea EGCG and turmeric curcumin — designed for direct integration into NDIN submissions and 21 CFR 111 audits:
- Complete specification sheets with purity profiles, residual solvents, heavy metals, and microbial limits
- Full manufacturing process descriptions including solvent identity, chromatographic parameters, and process controls
- GLP toxicology packages — Ames test, chromosomal aberration, and 90-day oral toxicity studies
- Batch-level Certificates of Analysis with validated HPLC methods and catechin/curcuminoid ratio fingerprinting
- NDIN Master File readiness — documentation structured for FDA Master File submission or right-of-reference authorization
Frequently Asked Questions
Is standard green tea extract (45% EGCG) exempt from NDI notification?
A crude ethanol-water extract with a composition matching products documented before October 15, 1994 may qualify as a grandfathered ingredient. However, if the process uses novel solvents or selective purification steps that significantly alter the chemical profile, an NDIN is required regardless of the source botanical's history.
Can I rely on another company's NDIN for the same ingredient?
No. FDA's March 2024 final guidance and its June 2025 fact sheet confirm that each manufacturer or distributor must submit its own NDIN. A prior firm's notification only covers your product if that NDIN specifically described your dietary supplement and its conditions of use. The new Master File program offers a compliant alternative: obtain a right of reference from the ingredient manufacturer's Master File.
